Lost in translation: Again, another failed neuroprotection trial

Neurology

Volumn 69, Issue 13, 2007, Pages 1308-1309

  Brew, Bruce James ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FRACTALKINE; GLUTAMIC ACID; JANUS KINASE; PLACEBO; QUINOLINIC ACID; SELEGILINE; TUMOR NECROSIS FACTOR ALPHA;

COGNITIVE DEFECT; DISEASE SEVERITY; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED NEUROCOGNITIVE DISORDER; HUMAN; KARNOFSKY PERFORMANCE STATUS; NEUROFILAMENT; NEUROMODULATION; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POST HOC ANALYSIS; PRIORITY JOURNAL; PSYCHOMOTOR DEVELOPMENT; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

AIDS DEMENTIA COMPLEX; ANTIOXIDANTS; BIOLOGICAL MARKERS; CLINICAL TRIALS; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NERVE DEGENERATION; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; SELEGILINE; TREATMENT FAILURE;

EID: 34748840331     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000277530.05450.ff     Document Type: Editorial

References (10)

1. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in HIV/AIDS infection across pre-HAART and HAART eras: a combined study of 2 cohorts. J Neurovirol 2004;10:350-357.
2. Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 2007;69:1314-1321.
3. Brew BJ. HAD and the need for new trial design methodology. AIDS 2007 (in press).
4. Antinori A, Arendt G, Becker JT, et al. Biomarkers of HIV-1 central nervous system injury and infection. Neurology 2007 (in press).
5. Abdulle S, Mellgren A, Brew BJ, et al. Cerebrospinal fluid neurofilament protein (NFL): a marker of active HIV related neurodegeneration. J Neurol 2007 Apr 10 [Epub ahead of print].
6. Neuroprotection: the end of an era? Lancet 2006;368.
7. Kieburtz K, Ravina B. Why hasn't neuroprotection worked in Parkinson's disease? Nat Clin Pract Neurol 2007;3:240-241.
8. Donnan GA. A new road map for neuroprotection: the Feinberg lecture. Stroke 2007 (in press).
9. Mirescu C, Gould E. From neurotoxin to neurotrophin. Nat Neurosci 2004;7:899-900.
10. Guillemin G, Croitoru J, Dormont D, Armati P, Brew BJ. Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes: implications for brain inflammation in AIDS. Glia 2003;41:371-381.